Introduction. Anatomical and topographic features of abundant pharyngeal innervation, causing pronounced symptoms of exacerbations of tonsillopharyngitis and significantly reducing the well-being of patients, will determine the improvement of treatment. Aim. To evaluate the possibility of using a nonsteroidal anti-inflammatory drug with the flurbiprofen in complex exacerbations of chronic tonsillopharyngitis. Materials and methods. The clinical observation of 117 patients with exacerbation of chronic tonsillopharyngitis was carried out. By random sampling, all patients were divided into 2 groups, where persons of the main group (n = 61) for standard conservative therapy took a tableted nonsteroidal anti-inflammatory drug with the active substance flurbiprofen 1 tablet with a 3–6-hour time interval during. Results and discussion. Оn day 3 of the therapy, a more pronounced improvement in both the severity of clinical complaints and pharyngoscopy data was noted to a greater extent in patients of the main group: a decrease in the severity of edema of the palatine tonsils by 1.6 points, vascular injection by 1.8 points, edema of the palatine arches by 2.2 points, hyperemia of the mucous membrane by 3.7 points. In the Conrol group (n = 56), there was a decrease in the severity of edema of the palatine tonsils by 1.4 points, vascular injection by 1.2 points, edema of the palatine arches by 1.7 points, hyperemia of the mucous membrane by 2.4 points. During the 7-day course of treatment, psychological health was restored by 24.8 points in the control group and by 32.3 points in the main group. An increase in vital activity was noted by 18.7 points in the control group and by 34.2 points in the main group, a clear increase in physical activity by 19.6 points and 7.6 points in the main and control groups, respectively. Conclusions. Earlier relief of inflammatory symptoms of exacerbations of tonsillopharyngitis and restoration of patient well-being when a nonsteroidal anti-inflammatory drug was included in complex therapy confirmed its good efficacy and safety. © 2024 Remedium Group Ltd. All rights reserved.